Navigation Links
Unigene Reports Third Quarter 2011 Financial Results
Date:11/9/2011

ment capabilities continue to generate near-term revenue from the six ongoing feasibility studies evaluating our ability to orally deliver synthetic and natural peptides.  The Company anticipates that at least one feasibility study will have the potential to convert into a high-value milestone and royalty payment licensing agreement over the next 9-12 months.

During the second quarter, the Unigene Biotechnologies strategy was validated by the signing of a Clinical Manufacturing Services Agreement with Cara Therapeutics, Inc.  Unigene will provide clinical supply material for Cara's Phase 1 study of investigational drug, CR845, a peripherally acting kappa opioid agonist being developed for the treatment of both acute and chronic pain. Cara's Phase 1 study is expected to begin before year end.

Unigene has already received strong validation of its recombinant manufacturing technology via the Company's out-licensing of its proprietary process to manufacture the active pharmaceutical ingredient in Novartis' oral calcitonin product candidate currently in active Phase 3 clinical trials for osteoporosis. Unigene expects that Novartis will announce Phase 3 osteoporosis trial results before year end.

Corporate InitiativesUnigene is committed to focusing its resources on high valuation drug development and peptide drug delivery opportunities.  On September 21, 2011, the Company divested its non-core asset, Site Directed Bone Growth (SDBG) by assigning seven patent applications to Kieran Murphy, LLC.  In addition, Unigene terminated an Exclusive License Agreement and Consulting Agreement with Kieran Murphy, LLC, as well as a License Option Agreement and Research Agreement with Yale University.  In exchange for the assignment of the patents, Unigene will receive sales royalties in excess of seven percent (7%) and will receive forty percent (40%) of any future licensing revenue and/or forty percent (40%) of all considerations rece
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011
2. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
3. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
4. GenVec Reports Third Quarter 2011 Financial Results
5. Chindex International, Inc. Reports Financial Results for the Third Quarter and First Nine Months of 2011
6. Allied Healthcare Products Reports First Quarter Loss on Sales Decline
7. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
8. Stereotaxis Reports Third Quarter Financial Results
9. Isis Reports Financial Results and Highlights for Third Quarter 2011
10. Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
11. Anadys Pharmaceuticals Reports Third Quarter 2011 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... addition of the "Investigation Report on China,s Tobramycin ... Tobramycin is a traditional antibiotic whose eye drop and ... treatment of potential infection or inflammation caused by eye ... are able to produce tobramycin, among which ...
(Date:8/28/2015)... 28, 2015 Patterson Medical, formerly the ... PDCO ), is now an independent company with ... Patterson Medical by Madison Dearborn Partners (MDP).  ... for a transition period before rebranding as the ... medicine products.  With the focused resources and expertise ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on ... their offering. Developed by Novo Nordisk, ... is an important drug for the treatment of ... a fast- acting insulin analog, starts working fast ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... April 12, 2011 New England Biolabs (NEB), a ... for life science research, announces that it has signed ... and Imperial Life Sciences (ILS), based in India. ... BIOKE, a Cell Signaling Technology (CST) Europe BV company, ...
... Novartis Pharmaceuticals Corporation ("Novartis") announced today that ... Drugs Advisory Committee (ODAC) recommended approval of Afinitor® ... advanced neuroendocrine tumors (NET) of pancreatic origin. ... data from the everolimus RADIANT (RAD001 In Advanced ...
Cached Medicine Technology:New England Biolabs Expands its Distribution Network through Collaborations in India and the Netherlands 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 3Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 4Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 5Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 6Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 7Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 8Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 9Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 10
(Date:8/28/2015)... , ... August 28, 2015 , ... An article ... local pizza maker Paul LaRocco has gone through to open a pizzeria in Westchester. ... permitting process tends to take several months, but the current process, having already gone ...
(Date:8/28/2015)... , ... August 28, 2015 , ... As reported ... Merz, received FDA clearance for results that last for two years, the longest ... news for patients who are looking for a long-lasting, effective solution for their cellulite, ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL —Pocket Protein™, ... fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch ... CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were selected ...
(Date:8/28/2015)... Neb. (PRWEB) , ... August 28, 2015 , ... Medical ... the 2015 Best Places to Work in Healthcare by Modern Healthcare and ... , Now in its eighth year, the Best Places to Work in ...
(Date:8/28/2015)... ... 2015 , ... SmartPractice Calendars afford dental offices ... contact information and logos, Calendars stand alone as functional brand-building giveaways ... mailings, thank you and welcome communications, and to complement statements and invoices. 2016 ...
Breaking Medicine News(10 mins):Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2
... threat, even without diet changes, study finds , , MONDAY, Dec. ... of the week is enough to undo metabolic syndrome, a ... stroke, a new study suggests. , "What we found was ... in improving metabolic syndrome risk," said study author Johanna L. ...
... researcher showed that acute and chronic constipation together accounted for ... children treated at one hospital. , The study also suggests ... when trying to determine the cause of abdominal pain in ... 962 children ages 4 to nearly 18, appear in the ...
... cardiac safety, TAMPA, Fla., Dec. 17 ... in electro-stun technology, today,announced a major research university ... Systems, S-200 projectile stun gun. Details of the,study ... meeting and/or,in a scientific journal. However, this study ...
... an effort to,help prepare today,s students to ... United Nations Environment Programme,s North,American Regional Office ... Day partnership and launched the International Children,s,Painting ... The International Children,s Painting Competition (ICPC) invites,elementary ...
... the nation in percentage of diabetes patients receiving,recommended ... claims, DALLAS, Dec. 17 The Dallas-Fort ... release of a new report on the,prevalence, costs ... 2 diabetes. The,Texas Type 2 Diabetes Report 2007 ...
... ATLANTA, December 17, 2007A new American Cancer Society report ... cancer cases and 7.6 million cancer deaths (about 20,000 ... comes from the first-ever Global Cancer Facts & Figures, ... of Facts & Figures publications. The report estimates that ...
Cached Medicine News:Health News:Moderate Exercise Cuts Risk of Metabolic Syndrome 2Health News:Moderate Exercise Cuts Risk of Metabolic Syndrome 3Health News:Constipation most common cause of children's abdominal pain 2Health News:Medical Study of Stinger S-200 Stun Gun Completed 2Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Northern New Jersey Elementary and Middle Schools 2Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Northern New Jersey Elementary and Middle Schools 3Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Northern New Jersey Elementary and Middle Schools 4Health News:Dallas-Fort Worth Business Group on Health Releases Report on the State of Diabetes in Texas 2Health News:Dallas-Fort Worth Business Group on Health Releases Report on the State of Diabetes in Texas 3Health News:New report estimates 12 million cancer cases worldwide 2
The only ergonomic work station of its kind with an optional built-in keratograph and flat-screen. The Concepta is a modern workstation for the examination and refraction of patients....
The natural look of 3 in 1 technology in virtually any prescription....
Dot matrix pattern for light eyed patients....
Natural eye color change for even the darkest of eyes....
Medicine Products: